ASCIA Submissions 2025
ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.
ASCIA lodged five submissions on 23 January 2025 in support for the following applications which are relevant to clinical immunology/allergy specialists, to be considered at the March 2025 meeting of the Pharmaceutical Benefits Advisory Committee (PBAC):
-
Extension of PBS listing of Dupixent® (dupilumab) for patients aged less than 12 years
ASCIA letter PBAC Dupixent 2025-01-23 121.54 KB -
PBS listing of a new strength of Xolair® (omalizumab)
ASCIA letter PBAC Xolair 2025-01-23119.62 KB -
New PBS listing of Omlyclo® (omalizumab)
ASCIA letter PBAC Omlyclo 2025-01-23117.80 KB -
Amendment to PBS listing of Remsima® SC (infliximab)
ASCIA letter PBAC Remsima SC 2025-01-23 119.47 KB -
New PBS listing of Ixifi® (infliximab)
ASCIA letter PBAC Ixifi 2025-01-23 117.85 KB
ASCIA provided two letters of support In January 2025 for allergy/immunology departments to the World Allergy Organisation (WAO) Center pf Excellence program.
A joint communication was submitted to the ACT Government on 17 February 2025 regarding the need for a public paediatric allergy clinic in the ACT, from Allergy & Anaphylaxis Australia (A&AA), the Australasian Society of Clinical Immunology and Allergy (ASCIA) and the National Allergy Council.
2025